Skip to content
1 min left
0% read
Adaptive Security logo

Adaptive Security

Investment Firm
New York, New York, USA
Founded 2023
74

Adaptive is a next-generation cybersecurity platform

Share:

Adaptive Cybersecurity Platform

Adaptive is a next-generation cybersecurity platform.

We're working with pioneering security teams to protect critical systems from AI-powered cyber attacks. Our customers today include one of the largest payment aggregators in the United States, hedge funds and private equity firms, regional and national banks, leading technology companies, and critical healthcare systems.

Join us in building the future of cybersecurity.

Frequently Asked Questions About Adaptive Security

Adaptive Security is a finance company. Adaptive is a next-generation cybersecurity platform

Adaptive is a next-generation cybersecurity platform. We're working with pioneering security teams to protect critical systems from AI-powered cyber attacks. Our customers today include one of the largest payment aggregators in the United States, hedge funds and private equity firms, regional an.

Adaptive Security has been operating since 2023. You can verify their legitimacy through their official website and social media presence.

Adaptive Security operates in the finance sector of the cryptocurrency industry. Compare Adaptive Security with other finance companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using Adaptive Security, research their track record (operating since 2023), verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. Adaptive Security is based in New York, New York, USA, has been operating since 2023. Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

Adaptive Security is based in New York, New York, USA, North America, with offices in New York, New York, USA, Beverly Hills, California, USA.

Adaptive Security was founded in 2023. The company currently has 74 employees.

Adaptive Security Details

Adaptive Security Offices (6)

Adaptive Security Tags

More About Adaptive Security

Work Model Details
Employees work from physical offices.

Latest from Academy

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

The Blast ecosystem has been crypto's most misunderstood narrative of 2026. While the market fixated on a 98.3% drawdown from all-time highs, less-publicized on-chain data tells a counterintuitive story. Three major protocol upgrades shipped since January 2025, 10% TVL growth appeared week-on-week in April, and 279,520 holders remain HODLing their positions on a chain the world has given up on.

7m
 Why Tokenlon's Revenue Doesn't Match Its Token Price

Why Tokenlon's Revenue Doesn't Match Its Token Price

DEX aggregation is "solved" in DeFi, right? 1inch, Jupiter, Paraswap have you covered. Except the data paints a different picture. Tokenlon quietly processes over $120 million in weekly trading volume and a 99.71% order success rate, yet remains shockingly absent from discussion in industry forums and panels. Either the market is correct and Tokenlon's fundamentals are not what we perceive, or a highly-traveled protocol has been willfully ignored.

Mia Halland logoMia HallandApr 26, 2026
8m
Sixty-Five Million in BioDAOs, BIO at One Cent

Sixty-Five Million in BioDAOs, BIO at One Cent

Bio Protocol's CEO recently revealed that PeptAI designed a new ADHD peptide candidate in 24 hours for roughly $1,500 in initial lab validation. While crypto traders focus on memecoins, Bio Protocol has quietly built a scientific funding platform backed by Pfizer Ventures, Binance Labs, and Arthur Hayes' Maelstrom Fund. The bio price trades at $0.031, down 96.5% from its all-time high of $0.889, despite $65M in combined BioDAO research funding and active clinical trials.

8m